LIFE News and Press, aTyr Pharma Inc. From 09/18/19

SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will be participating in two investor conference...

The following slide deck was published by aTyr Pharma, Inc. in conjunction with this Read more ...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking Ole Andreas Halvorsen's Viking Global...

SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive ...

Start Time: 17:00 End Time: 17:32 aTyr Pharma, Inc. (LIFE) Q2 2019 Earnings Conference Call August 14, 2019, 17:00 PM ET Company Participants Sanjay Shukla - President and CEO Jill Broadfoot - CFO Conference Call Participants Shawn Egan - Citi Yi Chen - H.C. Wainwright ...

aTyr Pharma (NASDAQ: LIFE ): Q2 GAAP EPS of -$1.80 beats by $0.94 . More news on: aTyr Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and webcast today, August 14, at 5:00pm EDT SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ...

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2019 results after the market c...

SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines, today announced the appointment of David Briscoe, MB, ChB, Director of the Transplant Research Program and Fellowship Pr...

SAN DIEGO, July 10, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will host a Key Opinion Leader (KOL) call and webcas...